Clinical characteristics, antimicrobial therapy and outcomes of patients with carbapenem-resistant gram-negative bacterial infections: A retrospective study in an Iranian teaching hospital
Authors:
- Hoda AbediHAHoda Abedi
- Samira Ghasemi GavartiSGSamira Ghasemi Gavarti
- Mansour SiavashMSMansour Siavash
- Mojtaba AkbariMAMojtaba Akbari
- Hamid SolgiHSHamid Solgi
Open Access
Abstract
No abstract availableFunding Information
- Isfahan University of Medical Sciences (58143)
This publication has 23 references indexed in Scilit:
- Failure of ceftazidime/avibactam experimental therapy in the treatment of Klebsiella pneumoniae ST11 co-producing NDM-1 and OXA-48 carbapenemases infectionEuropean Journal of Clinical Microbiology & Infectious Diseases, 2024
- Epidemiology and clinical characteristics of patients with healthcare-acquired multidrug-resistant Gram-negative bacilli: a retrospective study from a tertiary care hospitalScientific Reports, 2024
- Individualised, short-course antibiotic treatment versus usual long-course treatment for ventilator-associated pneumonia (REGARD-VAP): a multicentre, individually randomised, open-label, non-inferiority trialThe Lancet Respiratory Medicine, 2024
- An analysis of risk factors for carbapenem-resistant Enterobacteriaceae infectionJournal of Global Antimicrobial Resistance, 2022
- Comprehensive pan-genomic, resistome and virulome analysis of clinical OXA-48 producing carbapenem-resistant Serratia marcescens strainsGene, 2022
- Multicentre study of the main carbapenem resistance mechanisms in important members of the Enterobacteriaceae family in IranNew Microbes and New Infections, 2021
- Treatment outcome and adverse effects of colistin in adult patients with carbapenem-resistant gram-negative bacteremia from PakistanInternational Journal of Infectious Diseases, 2021
- ESBL-colonization at ICU admission: impact on subsequent infection, carbapenem-consumption, and outcomeInfection Control & Hospital Epidemiology, 2019
- Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trialThe Lancet Infectious Diseases, 2018
- Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by Acinetobacter baumannii and Pseudomonas aeruginosaOpen Forum Infectious Diseases, 2017